User interface enhancement report

The existing user interfaces to TEMPUS, Plaid, and other systems in the OSDS are fundamentally based on only two modes of communication: alphanumeric commands or data input and grapical interaction. The latter are especially suited to the types of interaction necessary for creating workstation objects with BUILD and with performing body positioning in TEMPUS. Looking toward the future application of TEMPUS, however, the long-term goals of OSDS will include the analysis of extensive tasks in space involving one or more individuals working in concert over a period of time. In this context, the TEMPUS body positioning capability, though extremely useful in creating and validating a small number of particular body positions, will become somewhat tedious to use. The macro facility helps somewhat, since frequently used positions may be easily applied by executing a stored macro. The difference between body positioning and task execution, though subtle, is important. In the case of task execution, the important information at the user's level is what actions are to be performed rather than how the actions are performed. Viewed slightly differently, the what is constant over a set of individuals though the how may vary

Systematic review and meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke: an update

Interleukin-1 receptor antagonist (IL-1 RA) is an anti-inflammatory protein used clinically to treat rheumatoid arthritis and is considered a promising candidate therapy for stroke. Here, we sought to update the existing systematic review and meta-analysis of IL-1 RA in models of ischaemic stroke, published in 2009, to assess efficacy, the range of circumstances in which efficacy has been tested and whether the data appear to be confounded due to reported study quality and publication bias. We included 25 sources of data, 11 of which were additional to the original review. Overall, IL-1 RA reduced infarct volume by 36.2 % (95 % confidence interval 31.6–40.7, n = 76 comparisons from 1283 animals). Assessments for publication bias suggest 30 theoretically missing studies which reduce efficacy to 21.9 % (17.3–26.4). Efficacy was higher where IL-1 RA was administered directly into the ventricles rather than peripherally, and studies not reporting allocation concealment during the induction of ischaemia reported larger treatment effects. The preclinical data supporting IL-1 RA as a candidate therapy for ischaemic stroke have improved. The reporting of measures to reduce the risk of bias has improved substantially in this update, and studies now include the use of animals with relevant co-morbidities. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12975-016-0489-z) contains supplementary material, which is available to authorized users